Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial by Vermorken, Jan B et al.
www.thelancet.com/oncology   Vol 14   July 2013 697
Articles
Cisplatin and ﬂ uorouracil with or without panitumumab in 
patients with recurrent or metastatic squamous-cell 
carcinoma of the head and neck (SPECTRUM): an open-label 
phase 3 randomised trial
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, 
Krzysztof Skladowski, Makoto Tahara, Vasant R Pai, Sandrine Faivre, Cesar R Blajman, Arlene A Forastiere, Brian N Stein, Kelly S Oliner, 
Zhiying Pan, Bruce A Bach, on behalf of the SPECTRUM investigators
Summary
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of 
patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN). We assessed 
the eﬃ  cacy and safety of panitumumab combined with cisplatin and ﬂ uorouracil as ﬁ rst-line treatment for 
these patients. 
Methods This open-label phase 3 randomised trial was done at 126 sites in 26 countries. Eligible patients were aged 
at least 18 years; had histologically or cytologically conﬁ rmed SCCHN; had distant metastatic or locoregionally 
recurrent disease, or both, that was deemed to be incurable by surgery or radiotherapy; had an Eastern Cooperative 
Oncology Group performance status of 1 or less; and had adequate haematological, renal, hepatic, and cardiac 
function. Patients were randomly assigned according to a computer-generated randomisation sequence (1:1; 
stratiﬁ ed by previous treatment, primary tumour site, and performance status) to one of two groups. Patients in 
both groups received up to six 3-week cycles of intravenous cisplatin (100 mg/m² on day 1 of each cycle) and 
ﬂ uorouracil (1000 mg/m² on days 1–4 of each cycle); those in the experimental group also received intravenous 
panitumumab (9 mg/kg on day 1 of each cycle). Patients in the experimental group could choose to continue 
maintenance panitumumab every 3 weeks. The primary endpoint was overall survival and was analysed by intention 
to treat. In a prospectively deﬁ ned retrospective analysis, we assessed tumour human papillomavirus (HPV) status 
as a potential predictive biomarker of outcomes with a validated p16-INK4A (henceforth, p16) immunohistochemical 
assay. Patients and investigators were aware of group assignment; study statisticians were masked until primary 
analysis; and the central laboratory assessing p16 status was masked to identiﬁ cation of patients and treatment. 
This trial is registered with ClinicalTrials.gov, number NCT00460265. 
Findings Between May 15, 2007, and March 10, 2009, we randomly assigned 657 patients: 327 to the panitumumab 
group and 330 to the control group. Median overall survival was 11·1 months (95% CI 9·8−12·2) in the panitumumab 
group and 9·0 months (8·1−11·2) in the control group (hazard ratio [HR] 0·873, 95% CI 0·729−1·046; p=0·1403). 
Median progression-free survival was 5·8 months (95% CI 5·6–6·6) in the panitumumab group and 4·6 months 
(4·1–5·4) in the control group (HR 0·780, 95% CI 0·659–0·922; p=0·0036). Several grade 3 or 4 adverse events 
were more frequent in the panitumumab group than in the control group: skin or eye toxicity (62 [19%] of 
325 included in safety analyses vs six [2%] of 325), diarrhoea (15 [5%] vs four [1%]), hypomagnesaemia (40 [12%] vs 
12 [4%]), hypokalaemia (33 [10%] vs 23 [7%]), and dehydration (16 [5%] vs seven [2%]). Treatment-related deaths 
occurred in 14 patients (4%) in the panitumumab group and eight (2%) in the control group. Five (2%) of the fatal 
adverse events in the panitumumab group were attributed to the experimental agent. We had appropriate samples 
to assess p16 status for 443 (67%) patients, of whom 99 (22%) were p16 positive. Median overall survival in patients 
with p16-negative tumours was longer in the panitumumab group than in the control group (11·7 months [95% CI 
9·7–13·7] vs 8·6 months [6·9–11·1]; HR 0·73 [95% CI 0·58–0·93]; p=0·0115), but this diﬀ erence was not shown for 
p16-positive patients (11·0 months [7·3–12·9] vs 12·6 months [7·7–17·4]; 1·00 [0·62−1·61]; p=0·998). In the control 
group, p16-positive patients had numerically, but not statistically, longer overall survival than did p16-negative 
patients (HR 0·70 [95% CI 0·47−1·04]).
Interpretation Although the addition of panitumumab to chemotherapy did not improve overall survival in an 
unselected population of patients with recurrent or metastatic SCCHN, it improved progression-free survival and 
had an acceptable toxicity proﬁ le. p16 status could be a prognostic and predictive marker in patients treated with 
panitumumab and chemotherapy. Prospective assessment will be necessary to validate our biomarker ﬁ ndings. 
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Introduction
Platinum-based combination chemotherapy regimens 
can be used to treat patients with incurable 
locoregionally recurrent or metastatic squamous-cell 
carcinoma of the head and neck (SCCHN).1 Although 
these regimens lead to tumour responses in about 
10–35% of patients, median survival is less than 1 year 
and the eﬀ ects on patients’ quality of life are unknown.2–6
Dysregulation of the EGFR signalling pathway plays a 
part in the development and progression of SCCHN.7,8 
Clinical trials6,9 have shown that addition of anti-EGFR 
monoclonal antibodies to chemotherapy improves 
clinical outcomes in patients with recurrent or metastatic 
SCCHN. In a randomised phase 3 study in the USA,6 
more patients in the group given cisplatin plus cetuximab 
responded than in the group receiving cisplatin plus 
placebo; and in a randomised phase 3 study (EXTREME) 
in Europe,9 addition of cetuximab to cisplatin and 
ﬂ uorouracil or to carboplatin and ﬂ uorouracil improved 
overall survival.
Human papillomavirus (HPV) DNA has been detected 
in up to two-thirds of oropharyngeal SCCHN tumours in 
patients presenting with locoregionally advanced 
disease.10,11 Patients with locoregionally advanced HPV-
positive oropharyngeal SCCHN who are treated with 
radiotherapy with or without chemotherapy have a better 
outlook than do HPV-negative patients.11–16 However, the 
global prevalence and prognostic eﬀ ect of HPV in 
patients with recurrent or metastatic SCCHN arising 
from the oropharynx, oral cavity, larynx, and hypopharynx 
is not well understood, particularly in the clinical trial 
setting. HPV-positive and HPV-negative SCCHN 
tumours diﬀ er in terms of biology, histology, genetic 
alterations, and prognosis.11,13,17,18 HPV-positive SCCHN 
tumours are characterised by the presence of high-risk 
HPV DNA (most commonly HPV 16) and the co-
expression of the viral oncoproteins E6 and E7, which 
modulate expression of key cellular proteins (such as the 
tumour suppressor p53 and retinoblastoma tumour-
suppressor protein), leading to upregulated expression of 
the cyclin-dependent kinase inhibitor p16-INK4A 
(henceforth, p16).10,18,19 How HPV status aﬀ ects the 
outlook of patients with recurrent or metastatic disease, 
or their response to treatment, is unknown. Some 
studies20–24 have suggested interactions between HPV and 
the EGFR signalling pathway. Therefore, HPV status (as 
assessed by p16 immunohistochemistry of formalin-
ﬁ xed paraﬃ  n-embedded samples) might aﬀ ect outcomes 
during anti-EGFR treatment.
Panitumumab is a fully human anti-EGFR monoclonal 
antibody that is used both as a single agent and combined 
with chemotherapy for treatment of metastatic colorectal 
cancer.25 Preclinical data for SCCHN cell lines and 
xenografts showed more antitumour activity with 
panitumumab plus radiotherapy than with radiotherapy 
alone,26 and phase 1 response data for panitumumab plus 
chemoradiotherapy have suggested that additional 
investigation of panitumumab in SCCHN is warranted.27 
In the Study of Panitumumab Eﬃ  cacy in Patients With 
Recurrent and/or Metastatic Head and Neck Cancer 
(SPECTRUM), we compared panitumumab plus 
cisplatin and ﬂ uorouracil with chemotherapy alone as 
ﬁ rst-line treatment for recurrent or metastatic SCCHN. 
Additionally, we investigated the relative eﬀ ect of 
treatment with panitumumab combined with chemo-
therapy in patients with recurrent or metastatic SCCHN 
who do (p16 positive) or do not (p16 negative) express 
p16.  
Methods
Study design and participants
This open-label phase 3 randomised trial was done at 
126 sites in 26 countries. Eligible patients were aged at 
least 18 years; had histologically or cytologically conﬁ rmed 
SCCHN; had distant metastatic or locoregionally recurrent 
disease, or both, that was deemed to be incurable by 
surgery or radiotherapy; had an Eastern Cooperative 
Oncology Group (ECOG) performance status of 1 or less; 
and had adequate haematological, renal, hepatic, and 
cardiac function. Patients who had received primary 
radiation therapy were eligible when locoregional 
recurrence was in the ﬁ eld of radiation and occurred at 
least 6 months after therapy completion, or when it was 
outside the ﬁ eld of radiation and occurred at least 
3 months after therapy completion. Patients were excluded 
if they had received previous systemic chemotherapy for 
recurrent or metastatic SCCHN (unless part of 
multimodality treatment for locoregionally advanced 
SCCHN completed more than 6 months before study 
entry); had another primary cancer with treatment within 
2 years of randomisation; had nasopharyngeal carcinoma 
or CNS metastases; had undergone major surgery in the 
previous 4 weeks or minor surgery in the previous 
2 weeks; or had received previous anti-EGFR treatment 
(unless part of initial curative multimodality therapy).
The study protocol was approved by independent ethics 
committees at each participating centre. All participants 
provided written informed consent. 
Randomisation and masking
Patients were randomly assigned (1:1) to one of two groups 
according to a computer-generated randomisation 
sequence (provided by an external vendor [ICON Clinical 
Research, North Wales, PA, USA]) with an automated 
interactive voice response system. Randomisation was 
stratiﬁ ed by previous treatment (newly diagnosed or 
previously untreated vs recurrent disease), primary tumour 
site (combined hypopharynx and oral cavity vs combined 
oropharynx and larynx), and ECOG performance status 
(0 vs 1). Double-blind treatment assignment was not 
possible because of the characteristic rash associated with 
EGFR inhibitors, including monoclonal antibodies such as 
panitumumab.28 Patients and investigators were aware of 
group assignment, and study statisticians were masked 
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until the primary analysis. Pathologists doing p16 
immunohistochemical assays were masked to patient 
identiﬁ cation and treatment.
Procedures
Patients in the panitumumab group received cisplatin 
and ﬂ uorouracil plus panitumumab, and those in the 
control group received cisplatin and ﬂ uorouracil alone. 
All patients received 100 mg/m² intravenous cisplatin on 
day 1 of a 3-week cycle, and 1000 mg/m² intravenous 
(continuous) ﬂ uorouracil infusion on days 1–4 of each 
cycle. Carboplatin (target area under the curve by the 
Calvert formula 5 mg/mL per min) could be permanently 
substituted for cisplatin when patients had creatinine 
clearance of less than 50 mL/min or grade 2 neurological 
toxicity (eg, sensory or motor neuropathy and ototoxicity). 
Patients in the panitumumab group received 9 mg/kg 
intravenous panitumumab on day 1 of each cycle 
immediately before receiving chemotherapy. 
Treatment continued until disease progression or for a 
maximum of six 3-week cycles. Patients who discontinued 
one study drug could receive the remaining drugs until 
completion of six cycles, disease progression, intolerable 
toxicity, or study withdrawal. Protocol-speciﬁ ed dose 
modiﬁ cations and interruptions of study drugs were 
allowed when patients experienced toxicity (appendix). 
Patients in the panitumumab group who had not had 
disease progression after six cycles could choose to 
receive panitumumab until disease progression, 
intolerable toxicity, or study withdrawal. 
Tumour response was assessed by CT or MRI at 
baseline and then every 6 weeks until disease progression. 
As per Response Evaluation Criteria in Solid Tumors 
(RECIST; version 1.0),29 complete or partial tumour 
responses were conﬁ rmed at least 4 weeks after the initial 
response assessment. Patients who discontinued 
treatment were followed up to obtain data for safety 
(30 days after the last treatment), survival (every 3 months 
until 3 years after the last patient underwent 
randomisation), and subsequent treatment for SCCHN 
(every 3 months until 3 years after the last patient 
underwent randomisation).
Adverse events occurring during the study were graded 
with the National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 3.0).30 Clinical and 
laboratory assessments were done at screening, on day 1 
of each cycle, and during safety follow-up. Serum 
samples for anti-panitumumab antibody analysis were 
obtained from patients in the panitumumab group 
before receiving infusions on day 1 of cycles 1 and 5, 
every 6 months thereafter, and at the safety follow-up 
visit. The serum samples were analysed as described 
previously.31
Core biopsies (1 mm) from available formalin-ﬁ xed 
paraﬃ  n-embedded SCCHN tumour blocks (primary or 
metastatic sites) were obtained, sectioned, reviewed by a 
pathologist, and used to construct a tumour microarray. 
In sites where blocks were not submitted, tissue slides 
were assessed. An immunohistochemical assay 
(p16INK4a Histology Kit, CINtec, Roche mtm laboratories 
AG, Heidelberg, Germany) that has been validated for 
testing of cervical cancer samples and qualiﬁ ed for 
assessment of p16 expression in SCCHN samples32 was 
used to determine tumour HPV status according to a 
prespeciﬁ ed plan. Tumour p16 expression was detected 
with the Clone E6H4 monoclonal antibody (Roche mtm 
laboratories AG, Heidelberg, Germany) and stained with 
a Nemesis Autostainer and diaminobenzidine secondary 
detection kit (Dako, Carpinteria, CA, USA). Samples were 
judged to be p16 positive when they had strong and 
diﬀ use nuclear and cytoplasmic staining in at least 10% of 
tumour cells;32 all other patients were deﬁ ned as p16 
negative. The immunohistochemical assay success rate 
was more than 99%.
Statistical analysis
The primary endpoint was overall survival (time from 
randomisation to death); patients who had not died at the 
time of the primary analysis were censored on the date 
that they were last known to be alive. An estimated 
470 deaths would provide 90% power to detect a hazard 
ratio (HR) of 0·7407, with an α of 0·05. With the 
assumptions that median overall survival in the control 
group would be 8·7 months (estimate based on 
assessment of clinical experience with platinum-based 
chemotherapy in recurrent or metastatic SCCHN) and 
an exponential distribution for overall survival, this HR 
would translate into a 35% relative and 3-month absolute 
327 received cisplatin and ﬂuorouracil 
         plus panitumumab (2 not treated)
330 received cisplatin and ﬂuorouracil 
         (5 not treated)
267 left study
         242 died
            10 withdrew consent
            14 lost to follow-up
               1 left because of 
                  administrative decision
283 left study
         241 died
            25 withdrew consent
            15 lost to follow-up
               2 left because of 
                  administrative decision
60 continued in study as of May 14, 2010 
      (3 continued to receive panitumumab)
47 continued in study as of May 14, 2010
765 patients screened
108 did not undergo randomisation
107 screening failure*
1 died
657 underwent randomisation 
         (intention-to-treat analysis)
Figure 1: Trial proﬁ le
*34 did not meet disease-related eligibility criteria, 20 laboratory failure, 10 timing or toxic eﬀ ects from previous 
treatment, 2 inadequate or inappropriate previous treatment, 1 withdrew consent, and 40 for other reasons. 
See Online for appendix
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increase in median overall survival. We estimated that 
650 patients would have to undergo randomisation in 
20 months and have about 18 months of follow-up. The 
maximum planned study duration was 56 months.
Secondary endpoints were progression-free survival 
(PFS; time from randomisation to disease progression or 
death), proportions of patients who achieved an objective 
response (complete and partial responses combined), 
duration of response (DOR; time from ﬁ rst conﬁ rmed 
objective response to disease progression, per RECIST), 
time to response (TTR; time from randomisation to ﬁ rst 
conﬁ rmed objective response), and safety.
The primary analysis of overall survival and PFS was 
done by intention to treat. We assessed numbers of 
objective responses, TTR, and DOR in patients with at 
least one one-dimensionally measurable lesion at 
baseline, per RECIST. All randomly assigned patients 
who received at least one dose of panitumumab or 
chemotherapy were included in the safety analysis. 
An independent data monitoring committee did interim 
safety analyses on a roughly annual basis during the 
treatment phase.
We did between-group comparisons of overall survival 
and PFS with log-rank tests stratiﬁ ed by randomisation 
factors. When the diﬀ erence in overall survival was not 
signiﬁ cant, all other p values were descriptive only. 
We estimated HRs and 95% CIs for overall survival and 
PFS with a Cox model stratiﬁ ed by randomisation 
factors. We used the Cochran-Mantel-Haenszel method33 
to assess the association between treatment group 
(panitumumab plus chemotherapy vs chemotherapy 
alone) and objective response (yes vs no), while 
controlling for randomisation stratiﬁ cation factors. 
We used the Wilson score method34 with continuity 
correction to calculate a 95% CI for the diﬀ erence in 
numbers of objective responses. For patients with an 
objective response, we estimated DOR with the 
Kaplan-Meier method, and assessed TTR with 
descriptive statistics. We did post-hoc analyses to assess 
diﬀ erences in adverse events between groups with 
Fisher’s exact test, with no correction for multiple 
comparisons. Analyses were done in SAS (version 9.2).
We assessed all patients in the intention-to-treat dataset 
with formalin-ﬁ xed paraﬃ  n-embedded tumour samples 
for p16 status. We used data from the primary analysis in 
the retrospective analysis of overall survival and PFS by 
tumour p16 status. We used an unstratiﬁ ed univariate 
Cox model for comparisons of overall survival and PFS 
between p16 groups, and unstratiﬁ ed log-rank tests and 
Cox models to assess the treatment eﬀ ect within p16 
groups.
This study is registered with ClinicalTrials.gov, number 
NCT00460265.
Role of the funding source
The study sponsor was involved in study design, in 
collaboration with the corresponding author and 
members of the SPECTRUM steering committee; 
provision of access to the raw data to the study 
biostatistician (ZP); data management; prespeciﬁ ed 
statistical analyses; and data interpretation. JBV and BB 
led development of the report; all authors (some of whom 
are employed by the funder) participated in the writing of 
the report. The study sponsor funded medical writing 
assistance. The corresponding author had full access to 
Panitumumab group (n=327) Control group (n=330)
Men 283 (87%) 287 (87%)
Women 44 (13%) 43 (13%)
Geographical region
North America 24 (7%) 25 (8%)
Western Europe 101 (31%) 116 (35%)
Asia-Paciﬁ c 54 (17%) 42 (13%)
South America 25 (8%) 31 (9%)
Eastern Europe 123 (38%) 116 (35%)
Ethnic origin
White 268 (82%) 271 (82%)
Black 4 (1%) 2 (1%)
Hispanic 13 (4%) 12 (4%)
Asian 25 (8%) 30 (9%)
Japanese 13 (4%) 7 (2%)
Other* 4 (1%) 8 (2%)
Age (years) 58 (53–63) 59 (53–64)
<65 268 (82%) 256 (78%)
≥65 59 (18%) 74 (22%)
Eastern Cooperative Oncology Group performance status
0 98 (30%) 98 (30%)
1 227 (69%) 228 (69%)
2† 2 (1%) 4 (1%)
Duration of disease (months) 15·0 (9·6–26·2) 15·9 (10·1–32·5)
Involuntary weight loss in the previous 6 months
0–5% 27 (8%) 28 (8%)
>5% 60 (18%) 68 (21%)
None or missing 240 (73%) 234 (71%)
Primary tumour site
Oropharynx 86 (26%) 96 (29%)
Hypopharynx 52 (16%) 37 (11%)
Larynx 100 (31%) 95 (29%)
Oral cavity 89 (27%) 102 (31%)
Extent of disease
Locoregional recurrence only 143 (44%) 126 (38%)
Distant metastatic 119 (36%) 123 (37%)
Distant metastatic and locoregionally 
recurrent
65 (20%) 81 (25%)
Primary tumour histological type
Well diﬀ erentiated 63 (19%) 63 (19%)
Moderately diﬀ erentiated 133 (41%) 123 (37%)
Poorly diﬀ erentiated 54 (17%) 70 (21%)
Undiﬀ erentiated 6 (2%) 6 (2%)
Not otherwise speciﬁ ed/unknown 71 (22%) 68 (21%)
(Continues on next page)
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all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between May 15, 2007, and March 10, 2009, we randomly 
assigned 657 patients to the two treatment groups 
(ﬁ gure 1). Baseline characteristics were similar in the two 
groups (table 1). Seven patients did not receive treatment 
(ﬁ gure 1); 325 patients in each group received at least one 
dose of panitumumab or chemotherapy and were 
included in safety analyses. 
Of the 327 patients assigned to the panitumumab 
group, all discontinued chemotherapy (reasons given for 
discontinuation of each component; some patients 
counted more than once): 155 completed protocol-
speciﬁ ed chemotherapy, 55 did not meet protocol-
speciﬁ ed criteria (29 had creatinine clearance 
<50 mL/min; 26 had grade 2 or 3 neurotoxicity), 46 had 
disease progression, 45 had an adverse event, 36 died, 
31 requested discontinuation, eight withdrew consent, 
six were non-compliant, four were lost to follow-up, one 
was ineligible, and 15 for other reasons. 324 patients 
discontinued panitumumab at any point while in the 
study: 144 had disease progression, 48 requested 
discontinuation, 43 had an adverse event, 41 died, eight 
withdrew consent, seven were non-compliant, ﬁ ve were 
lost to follow-up, one was ineligible, and 27 for other 
reasons. Of the 330 assigned to the control group, all 
discontinued chemotherapy: 128 completed protocol-
speciﬁ ed chemotherapy, 76 did not meet protocol 
speciﬁ ed criteria (55 had creatine clearance <50 mL/min; 
20 had grade 2 or 3 neurotoxicity; 1 had grade 4 
neurotoxicity), 88 had disease progression, 47 had adverse 
event, 29 died, 16 requested discontinuation, 19 withdrew 
consent, ﬁ ve were non-compliant, two were lost to follow-
up, one was ineligible, and 15 for other reasons.
At the time of the primary analysis on May 14, 2010, 
550 patients had left the study: 483 had died, 35 had 
withdrawn their consent, 29 were lost to follow-up, and 
three left because of decisions made by the study 
oversight team. 153 patients in the panitumumab group 
and 147 patients in the control group received at least one 
subsequent treatment for SCCHN after discontinuation 
of protocol-speciﬁ ed treatment: 97 in the panitumumab 
group and 84 the control group received additional 
cytotoxic chemotherapy; 50 and 46 radiotherapy or 
surgery, or both; and 15 and 31 anti-EGFR monoclonal 
antibody therapy. 
The median relative dose intensity of panitumumab 
during the study (proportion given of amount planned) was 
91% (IQR 83–98). The median number of 3-week cycles in 
which panitumumab was given was ﬁ ve (three to eight). 
The median duration of panitumumab treatment was 
18·3 weeks (9·3−26·9). At least one dose of panitumumab 
was withheld for 39 patients (12%). 126 patients (39%) in 
the panitumumab group were eligible to continue 
panitumumab after completing six cycles of chemotherapy 
and panitumumab. 95 patients (75% of those eligible; 29% 
of all patients in the panitumumab group) continued with 
panitumumab maintenance treat ment, and went on to 
receive a median of three cycles (IQR two to eight) of 
panitumumab monotherapy. Panitumumab monotherapy 
varied by region (appendix). 
The median relative dose intensity of cisplatin was 87% 
(IQR 75–97) in the panitumumab group and 85% (72–98) 
in the control group, and the median relative dose 
intensity of carboplatin was 95% (84–100) and 98% 
(86–100). The median number of cisplatin cycles was 4·0 
(2·0–6·0) in the panitumumab group and 4·0 (2·0–5·0) 
in the control group. The median number of carboplatin 
cycles was 2·0 (2·0–4·0) in the panitumumab group and 
4·0 (2·0–5·0) in the control group. The median duration 
of cisplatin treatment was 13·4 weeks (7·9−19·3) in the 
panitumumab group and 13·0 weeks (6·4−18·4) in the 
control group. Overall, 155 patients (24%; 69 [21%] in the 
panitumumab group; 86 [26%] in the control group) 
switched from cisplatin to carboplatin. Fewer patients in 
the panitumumab group (29 [42%]) than in the control 
group (52 [60%]) switched because of a creatinine 
clearance of less than 50 mL/min. The median time to 
switching from cisplatin to carboplatin for any reason 
was 64 days (IQR 34−106) in the panitumumab group and 
77 days (43−106) in the control group.
The median relative dose intensity of ﬂ uorouracil was 
89%  (79–97) in the panitumumab group and 90% 
(79–99) in the control group. The median number of 
ﬂ uorouracil cycles was 5·0 (3·0–6·0) in the panitumumab 
group and 4·0 (2·0–6·0) in the control group. The 
median duration of ﬂ uorouracil treatment was 
17·9 weeks (9·1−20·0) in the panitumumab group and 
15·0 weeks (7·0−19·9) in the control group. 
Median overall survival was 11·1 months (95% CI 
9·8–12·2) in the panitumumab group and 9·0 months 
Panitumumab group (n=327) Control group (n=330)
(Continued from previous page)
Previous treatment‡
Chemotherapy or radiotherapy, or both 267 (82%) 263 (80%)
Chemotherapy
Platinum 128 (39%) 113 (34%)
Fluoropyrimidine 52 (16%) 44 (13%)
Taxane 7 (2%) 8 (2%)
Methotrexate 9 (3%) 6 (2%)
Other 15 (5%) 18 (5%)
Radiotherapy 266 (81%) 259 (78%)
Patients with locoregionally advanced 
disease
189 (58%) 187 (57%)
Surgery 282 (86%) 284 (86%)
Data are n (%) or median (range). *Australian Aboriginal, or unknown or missing. †Enrolled patients with a 
performance status of 2 were protocol violations. ‡Previous treatment given as adjuvant or part of multimodality 
treatment in locoregionally advanced disease >6 months before randomisation. 
Table 1: Baseline characteristics 
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Figure 2: Kaplan-Meier curves 
by group (A) and subgroup 
analyses (B) for overall 
survival 
*From local pathologist 
assessments on case report 
form.
All patients
Eastern Cooperative Oncology Group performance status
0
1
Primary site
Oral cavity
Hypopharynx
Oropharynx
Larynx
Age
<55 years
≥55 years
Region
Western Europe
Eastern Europe
Asia-Paciﬁc
North and South America
>5% weight loss
Yes
No
Previous platinum-based chemotherapy
Yes
No
Previous single modality radiotherapy
Yes
No
Locally recurrent and distant metastases
Tumour diﬀerentiation*
Well
Moderate
Poorly or undiﬀerentiated
Not otherwise speciﬁed
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Figure 3: Kaplan-Meier curves 
by group (A) and subgroup 
analyses (B) for progression-
free survival
*From local pathologist 
assessments on case report 
form.
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(8·1–11·2) in the control group (p=0·1403; HR 0·873, 95% 
CI 0·729–1·046; ﬁ gure 2). Median follow-up was 
44·0 weeks (IQR 21·0−75·0) in the panitumumab group 
and 35·0 weeks (16·0−66·0) in the control group. At the 
time of analysis, 242 patients (74%) in the panitumumab 
group and 241 (73%) in the control group had died. 
We assessed the proportional hazards assumption between 
the treatment groups with graphical and numerical 
methods based on cumulative Martingale residuals and 
recorded no evidence of non-proportionality (p=0·16).
Median PFS was 5·8 months (95% CI 5·6–6·6) in the 
panitumumab group and 4·6 months (4·1–5·4) in the 
control group (HR 0·780, 95% CI 0·659–0·922; 
p=0·0036; ﬁ gure 3). At the time of analysis, 290 patients 
(89%) in the panitumumab group and 275 (83%) in the 
control group had progressed or died. Sensitivity analyses 
suggested minor non-proportionality between treatment 
groups for PFS, but the results were consistent with 
those from the primary analysis (data not shown).
Overall, 566 patients had at least one baseline 
radiologically one-dimensionally measurable lesion. 
The proportions of participants who had an objective 
response (odds ratio 1·69, 95% CI 1·15–2·44; p=0·0065) 
or achieved disease control (odds ratio 1·84, 1·21–2·81; 
p=0·0038) were signiﬁ cantly higher in the panitumumab 
group than in the control group (table 2). Median DOR 
and median TTR were similar in the two groups (table 2). 
Subgroup analyses of overall survival and PFS 
suggested that the results for overall survival (ﬁ gure 2) 
Figure 4: Overall survival by group in (A) western Europe, (B) North and South America, (C) eastern Europe, and (D) the Asia-Paciﬁ c region 
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Control group
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A B
C D
 Panitumumab group (n=327) Control group (n=330)
Included in tumour response analysis 278 (85%) 288 (87%)
Complete response 5 (2%) 5 (2%)
Partial response 96 (35%) 68 (24%)
Stable disease 128 (46%) 134 (47%)
Disease progression 18 (6%) 34 (12%)
Not assessable 2 (1%) 3 (1%)
Not done 29 (10%) 44 (15%)
Objective response (complete response and 
partial response)
101 (36%, 31–42) 73 (25%, 20–31)
Disease control (complete response, partial 
response, and stable disease)
229 (82%, 77–87) 207 (72%, 66–77)
Time to response (weeks) 6·1 (5·9–11·0) 6·7 (5·9–11·3)
Duration of response (months)* 5·6 (4·8–6·2) 5·7 (4·7–6·2)
Data are n (%), n (%, 95% CI), or median (IQR). *Included only patients who had an objective response.
Table 2: Best overall response
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and PFS (ﬁ gure 3) were consistent across most patient 
subgroups. Of note, median overall survival and HRs 
varied by geographic region (ﬁ gure 4, table 3). 
In univariate and multivariate analyses, several 
baseline covariates (such as previous platinum 
chemotherapy, ECOG performance status, weight loss in 
the previous 6 months, and disease stage) were 
signiﬁ cantly associated with overall survival (appendix). 
The eﬀ ect of panitumumab in the multivariate model 
(HR 0·875, 95% CI 0·731−1·048; p=0·146) was consistent 
with that in the primary analysis (appendix).
Grade 3 or 4 treatment-emergent adverse events were 
generally more common in the panitumumab group 
than in the control group (table 4). Diﬀ erences between 
groups were signiﬁ cant for skin or eye toxicity (p<0·0001); 
hypomagnesaemia (p<0·0001); cardiac arrhythmias 
(p=0·0474); and diarrhoea (p=0·0175). Grade 3 or 4 
infusion reactions were rare (table 4). Serious adverse 
events occurred in 157 (48%) of 325 patients in the 
panitumumab group included in the safety analyses and 
139 (43%) of 325 in the control group. Adverse events 
resulting in discontinuation of panitumumab or 
chemotherapy, or both, or removal from the study 
occurred in 91 patients (28%) in the panitumumab group 
and 78 patients (24%) in the control group. Of these 
patients, 69 patients in the panitumumab group and 
59 in the control group discontinued because of 
treatment-related toxicity. 
Overall, 48 (15%) of the 325 patients in the panitumumab 
group and 41 (13%) of 325 in the control group included 
in safety analyses had on-treatment fatal adverse events. 
Death and disease progression occurred simultaneously 
in 12 patients in the panitumumab group and 17 patients 
in the control group. Other fatal adverse events were 
cardiac events (eight patients [2%] in the panitumumab 
group; seven [2%] in the control group), sepsis or febrile 
neutropenia (four [1%]; three [1%]), and haemorrhage 
(two [1%]; ﬁ ve [2%]). By investigator attribution, treatment-
related deaths occurred in 14 patients (4%) in the 
panitumumab group and eight (2%) in the control group. 
Five patients (2%) had fatal adverse events that were 
attributed to panitumumab by the investigators: 
myocardial infarction, cardiac failure, cerebrovascular 
accident, acute renal failure, and haemorrhagic diarrhoea. 
Fatal adverse events within the ﬁ rst 30 days of treatment 
occurred in 14 patients (4%) in the panitumumab group 
and 13 patients  (4%) in the control group. 
Of 298 patients who received panitumumab and for 
whom serum samples were available for testing, three (1%) 
developed anti-panitumumab antibodies. However, no 
anti-panitumumab-neutralising antibodies were detected.
Fixed-formalin paraﬃ  n-embedded tumour samples 
were available for assessment of p16 status for 443 (67%) 
 Panitumumab group (n=325) Control group (n=325)
Grade 3 or 4 Grade 4 Grade 3 or 4 Grade 4
Patients with any event 219 (67%) 96 (30%) 214 (66%) 81 (25)
Adverse events of interest
Skin or eyes, or both* 62 (19%) 5 (2%) 6 (2%) 0
Hypomagnesaemia 40 (12%) 15 (5%) 12 (4%) 4 (1%)
Hypokalaemia 33 (10%) 9 (3%) 23 (7%) 10 (3%)
Stomatitis or oral mucositis 29 (9%) 2 (1%) 28 (9%) 2 (1%)
Cardiac arrhythmias 19 (6%) 3 (1%) 8 (2%) 5 (2%)
Dehydration 16 (5%) 2 (1%) 7 (2%) 0
Diarrhoea 15 (5%) 1 (<1%) 4 (1%) 1 (<1%)
Venous embolic and thrombotic events 13 (4%) 8 (2%) 6 (2%) 4 (1%)
Acute renal failure 10 (3%) 3 (1%) 11 (3%) 1 (<1%)
Hypocalcaemia 8 (2%) 5 (2%) 7 (2%) 2 (1%)
Embolic and thrombotic events 
(unspeciﬁ ed or mixed vessel type)
7 (2%) 3 (1%) 5 (2%) 1 (<1%)
Arterial embolic and thrombotic events 5 (2%) 3 (1%) 1 (<1%) 1 (<1%)
Infusion reaction† 2 (1%) 0 0 0
Ischaemic heart disease 2 (1%) 0 0 0
Interstitial lung disease 1 (<1%) 1 (<1%) 1 (<1%) 0
Severe cutaneous adverse reactions 1 (<1%) 1 (<1%) 0 0
Impaired or delayed wound healing 0 0 1 (<1%) 1 (<1%)
Haematological toxicity 141 (43%) 64 (20%) 147 (45%) 55 (17%)
Neutropenia 103 (32%) 43 (13%) 106 (33%) 40 (12%)
Anaemia 39 (12%) 5 (2%) 47 (14%) 5 (2%)
Thrombocytopenia 21 (6%) 9 (3%) 25 (8%) 8 (2%)
Febrile neutropenia 20 (6%) 12 (4%) 17 (5%) 6 (2%)
Adverse events were coded using Medical Dictionary for Regulatory Activities (version 13.0) and graded according to 
National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0), with the exception of some 
dermatological or skin adverse events that were graded with modiﬁ cations to the criteria. *Includes preferred terms 
considered related to skin and eye toxicity. †Per US prescribing information.
Table 4: Treatment-emergent adverse events in the safety analyses
Panitumumab group Control group Hazard ratio Log-rank 
p value
Died Overall survival (months) Died Overall survival (months)
Western Europe 69/101 (68%) 11·7 (8·4–14·9) 86/116 (74%) 9·7 (7·4–12·1) 0·727 (0·529–0·999) 0·0478
North and South 
America
39/49 (80%) 11·7 (8·2–13·9) 47/56 (84%) 7·8 (6·4–11·7) 0·692 (0·450–1·065) 0·0914
Eastern Europe 96/123 (78%) 10·3 (9·6–12·6) 81/116 (70%) 9·0 (6·6–13·4) 1·108 (0·823–1·492) 0·5004
Asia-Paciﬁ c region 38/54 (70%) 11·5 (7·4–15·1) 27/42 (64%) 11·7 (6·4–20·1) 0·985 (0·600–1·616) 0·9526
Data are n/N (%), median (95% CI), or hazard ratio (95% CI), unless otherwise stated.
Table 3: Overall survival in the two treatment groups by region
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of 657 patients, yielding 1083 evaluable tumour cores. 
99 (22%) of these 443 had p16-positive tumours and 
344 (78%) had p16-negative tumours (table 5, appendix).
The cumulative frequency distribution of p16-positive 
samples is shown in the appendix. The proportion of 
patients with p16-positive tumours was similar in the two 
groups: 57 (24%) of 236 in the panitumumab group, and 
42 (20%) of 207 in the control group (table 4). Many p16-
positive patients had oropharyngeal tumours (table 4). 
The proportions of patients with diﬀ erent sites of tumour 
origin were generally consistent between patients who 
could and could not be assessed for p16 status (table 4). 
Demographic and baseline characteristics were generally 
balanced between treatment groups in p16-negative and 
p16-positive patients (data not shown). Furthermore, the 
proportions of patients who had previously received 
platinum-based chemotherapy diﬀ ered between groups 
for both p16-negative (73 [41%] of 179 in the panitumumab 
group vs 55 [33%] of 165 in the control group) and p16-
positive patients (21 [37%] of 57 patients vs 21 [50%] of 42).
Median overall survival in patients with p16-negative 
tumours was longer in the panitumumab group than in 
the control group, but not in those with p16-positive 
tumours (ﬁ gure 5, table 6). Similarly, median PFS in 
patients with p-16 negative tumours was longer in the 
panitumumab group than in the control group, but not 
in those with p16-positive tumours (ﬁ gure 5, table 6).  
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Figure 5: Overall and progression-free survival by p16 status
Overall survival in p16-positive (A) and p16-negative (B) patients. Progression-free survival in p16-positive (C) and p16-negative (D) patients. p16=p16-INK4A.
Assessable 
for p16 
(n=443)
Not 
assessable 
for p16 
(n=214)
p16 positive (n=99) p16 negative (n=344)
Panitumumab 
group (n=57)
Control 
group 
(n=42)
Panitumumab 
group (n=179)
Control 
group 
(n=165)
Hypopharynx 61 (14%) 28 (13%) 5 (9%) 3 (7%) 34 (19%) 19 (12%)
Oral cavity 119 (27%) 72 (34%) 12 (21%) 6 (14%) 49 (27%) 52 (32%)
Larynx 137 (31%) 58 (27%) 16 (28%) 10 (24%) 58 (32%) 53 (32%)
Oropharynx 126 (28%) 56 (26%) 24 (42%) 23 (55%) 38 (21%) 41 (25%)
p16=p16-INK4A.
Table 5: Primary tumour site by p16 status 
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Of patients in the control group, those who were p16 
positive had numerically, but not statistically signiﬁ cantly, 
longer median overall survival than did those who were 
p16 negative (12·6 months [7·7–17·4] vs 8·6 months 
[6·9–11·1]; HR 0·70, 95% CI 0·47−1·04; ﬁ gure 6). Toxicity 
was generally similar between p16-negative and p16-
positive patients, and between patients of diﬀ erent 
p16 status in the two treatment groups (appendix).
Discussion
SPECTRUM was a global study of a geographically 
diverse population of patients with wide variation in 
previous treatment. The results show that the addition of 
panitumumab to a regimen of cisplatin and ﬂ uorouracil 
does not signiﬁ cantly improve overall survival of patients 
with recurrent or metastatic SCCHN. By contrast, both 
progression-free survival and frequency of objective 
response were signiﬁ cantly improved by the addition of 
panitumumab, conﬁ rming its antitumour activity in 
SCCHN. Furthermore, in a prospectively deﬁ ned 
retrospective analysis of p16 tumour status, we showed 
that overall survival was longer for p16-positive patients 
than for p16-negative patients who received only cisplatin 
and ﬂ uorouracil, suggesting that p16 status could be used 
as a prognostic marker in recurrent or metastatic 
SCCHN. Notably, the addition of panitumumab to the 
regimen resulted in signiﬁ cant improvements in overall 
and progression-free survival in patients with p16-
negative tumours, but not in those with p16-positive 
tumours. 
Two features of the primary analysis are noteworthy. 
First, median overall survival in both groups was longer 
than in two randomised studies.6,9 Median overall survival 
and progression-free survival in the group given cisplatin 
and ﬂ uorouracil alone were unexpectedly better than 
those in the previous studies (overall survival 
range 7·4−8·0 months; progression-free survival 
2·7−3·3 months).6,9 Second, we recorded regional 
variation in the eﬀ ect of panitumumab on overall 
survival, which potentially aﬀ ected the aggregate results. 
The inclusion of patients from the Asia-Paciﬁ c region 
(who had fairly long overall survival) might account, at 
least partly, for the extended overall survival in the control 
group compared with that in EXTREME9 (9·0 months vs 
7·4 months). 
We showed numerically, but not signiﬁ cantly, longer 
overall survival in the group given panitumumab for 
most subgroups. We recorded suggestions of increased 
beneﬁ ts in subgroups known to have poor outlooks, such 
as those who had greater than 5% weight loss, previous 
platinum exposure, and moderately and well 
diﬀ erentiated tumour subtypes. Progression-free survival 
was longer for patients who received panitumumab in 
most subgroups. The univariate and multivariate 
prognostic factors for overall survival identiﬁ ed in our 
study (performance status at study entry, weight loss, and 
previous platinum chemotherapy) were consistent with 
those previously reported by Argiris and colleagues.35 
The HPV analysis, in which p16 immunohistochemistry 
was used as a surrogate marker, showed that a p16-
positive status was a prognostic factor. This ﬁ nding is 
especially noteworthy because it extends results of 
previous studies in which tumour HPV status was shown 
to have prognostic value in patients with locoregionally 
advanced oropharyngeal SCCHN treated with 
chemotherapy or radiotherapy, or both.11–16 In our study, 
about half of p16-positive tumours were oropharyngeal, 
and the rest of p16-positive patients had laryngeal, 
p16-positive patients p16-negative patients
Panitumumab 
group
Control group Hazard ratio Log-rank 
p value
Panitumumab 
group
Control group Hazard ratio Log-rank 
p value
Died 42/57 (74%) 30/42 (71%) ·· ·· 133/179 (74%) 133/165 (81%) ·· ··
Overall survival 
(months)
11·0 (7·3–12·9) 12·6 (7·7–17·4) 1·00 (0·62–1·61) 0·998 11·7 (9·7–13·7) 8·6 (6·9–11·1) 0·73 (0·58–0·93) 0·0115
Progressed 54/57 (95%) 36/42 (86%) ·· ·· 160/179 (89%) 148/165 (90%) ·· ··
Progression-free 
survival (months)
5·6 (4·4–6·5) 5·5 (3·4–6·7) 1·08 (0·71–1·65) 0·730 6·0 (5·6–6·9) 5·1 (4·1–5·5) 0·69 (0·55–0·87) 0·0013
Data are n/N (%), median (95% CI), or hazard ratio (95% CI), unless otherwise stated.
Table 6: Overall and progression-free survival in the two treatment groups by p16 status
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Figure 6: Overall survival in control group by p16 status
p16=p16-INK4A.
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hypopharyngeal, and oral tumours, which is consistent 
with previous ﬁ ndings.36,37 The relative importance of 
HPV status in diﬀ erent SCCHN sites of origin remains 
to be deﬁ ned in future clinical investigation. The 
proportion of p16-positive patients deﬁ ned with our 
prespeciﬁ ed deﬁ nition of strong and diﬀ use nuclear and 
cytoplasmic staining in at least 10% of tumour cells was 
also consistent with previous studies;36,37 results were 
similar when alternative cutoﬀ s were used.
Notably, we showed that tumour p16 status might be a 
predictive biomarker for overall and progression-free 
survival in patients with recurrent or metastatic SCCHN 
treated with an anti-EGFR monoclonal antibody 
combined with chemotherapy. Furthermore, our results 
suggest that, in addition to the apparent eﬀ ects of 
regional variation, variation in tumour p16 status could 
have aﬀ ected the aggregate outcome results. The 
randomisation stratiﬁ cation of patients by combined 
tumour site (hypopharynx or oral cavity vs oropharynx or 
larynx) might have resulted in unequal stratiﬁ cation of 
patients with p16-positive tumours (most of whom had 
oropharyngeal tumours) between the two groups.
Our results raise important questions about tumour 
HPV status as a potential predictive biomarker in recurrent 
or metastatic SCCHN. SCCHN associated with HPV 
infection seems to be a biologically distinct subset of 
SCCHN, particularly with regard to diﬀ erences in genetic 
alterations between HPV-positive and HPV-negative 
disease.11,13,17,18 When tested as a speciﬁ c immuno histo-
chemical marker for HPV oncogene expression, p16 with a 
10% cutoﬀ  is robust,38 and has high concordance with 
high-risk HPV DNA, RNA, and E6 and E7 gene 
expression.39–41 Immunohistochemical detection of p16 has 
been successfully used in several clinical studies of patients 
with SCCHN as a screening marker to estimate HPV 
status.12,41–43 However, genetic diﬀ erences between SCCHN 
types might aﬀ ect the predictive ability of p16 as a 
biomarker.44 We assessed p16 status as a biomarker by 
tumour site of origin. In view of the number of patients 
with each of the tumour types in our study, further research 
will be required to resolve the issue of genetic variation. 
The results for overall survival in our primary analysis 
are surprising when compared with the phase 3 
EXTREME study,9 in which overall survival was improved 
in patients who received cetuximab plus cisplatin or 
carboplatin and ﬂ uorouracil compared with those who 
did not receive cetuximab (10·1 vs 7·4 months; HR 0·80; 
p=0·04). Although heterogeneity in populations of 
patients makes comparisons between trials diﬃ  cult, 
diﬀ erences between the two studies in design and patient 
eligibility criteria could explain, at least partly, the varying 
ﬁ ndings. First, in the EXTREME study,9 continuation of 
cetuximab monotherapy after six cycles of chemotherapy 
was mandatory for patients who had not experienced 
disease progression, whereas in our trial, continuation of 
panitumumab monotherapy was optional. 
Second, treatment received before enrolment diﬀ ered 
greatly between the two studies (previous chemotherapy: 
81% in our study vs 38% in EXTREME9). In our study, 
patients were not stratiﬁ ed by type of previous treatment, 
which also varied by region. Moreover, patients in 
EXTREME were allowed to receive either cisplatin or 
carboplatin from enrolment, whereas in our study, 
patients had to begin cisplatin and could only switch to 
carboplatin for reduced creatinine clearance (<50 mL/min) 
or grade 2 neurotoxicity. This requirement could have 
resulted in enrolment of a population with improved 
performance status, and therefore longer overall survival, 
compared with EXTREME.9
Third, in the EXTREME study,9 most patients were 
recruited from western Europe, whereas we recruited 
worldwide, with a third of patients from western Europe. 
In a subgroup analysis, we showed that overall survival 
was longer in patients from western Europe who received 
panitumumab than in those who did not. 
Fourth, overall survival, but not progression-free 
survival, in our trial might have been confounded by 
treatment given after progression, including cytotoxic 
chemotherapy and targeted agents. Although roughly 
5% of patients who received panitumumab plus 
chemotherapy and 9% of those who received 
chemotherapy alone received subsequent anti-EGFR 
targeted therapy for disease progression, the fairly 
infrequent crossover suggests that this potential 
confounder had a small eﬀ ect. Finally, unlike in 
Panel: Research in context
Systematic review
We did not do a formal systematic analysis before the start of our trial. We carefully 
reviewed reports of clinical trials assessing platinum-based chemotherapy treatment in 
recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN) that were 
identiﬁ ed by a search of PubMed and abstracts from international clinical oncology 
meetings. The review showed that overall survival in this population remains poor despite 
presently available treatments and that anti-EGFR agents might have activity in this 
setting. On the basis of this review and discussions with researchers and clinical 
oncologists, improvement in overall response and overall survival was evidently a realistic 
goal for a clinical trial in this population of patients.
Interpretation
As far as we are aware, SPECTRUM is the largest global study of an EGFR inhibitor in 
combination with platinum and high-intensity infusional ﬂ uorouracil chemotherapy in a 
diverse population of patients with recurrent or metastatic SCCHN. Overall survival did 
not signiﬁ cantly improve with the addition of panitumumab to the chemotherapy 
regimen, but we did record improvements in progression-free survival and objective 
response. Furthermore, in a retrospective analysis, a negative tumour human 
papillomavirus status, assessed by p16 immunohistochemistry, predicted overall and 
progression-free survival after treatment with cisplatin and ﬂ uorouracil plus 
panitumumab. Moreover, a p16-positive status was a favourable prognostic marker in 
patients who received only chemotherapy, suggesting a potential prognostic eﬀ ect in this 
population of patients.Our results indicate that tumour p16 status, regional diﬀ erences in 
overall survival, and other factors (eg, the intensity and amount of previous treatment) 
might be important considerations in the design of future global trials in recurrent or 
metastatic SCCHN. 
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EXTREME,9 we did not insist that all patients had to have 
disease that could be measured with RECIST at 
enrolment, which was appropriate because the primary 
endpoint was overall survival and means the results can 
be generalised to a broad population. 
Notably, overall survival of p16-negative patients in our 
study was longer than that in EXTREME (10·1 months in 
group given chemotherapy plus cetuximab; 7·4 months 
in group given chemotherapy alone).9 The results of a 
retrospective analysis of tumour p16 status in EXTREME,45 
which are qualitatively diﬀ erent from ours, suggested 
that the survival beneﬁ t of cetuximab treatment was 
independent of tumour p16 status. However, only 
44 (12%) of 381 assessable patients in EXTREME were 
identiﬁ ed as being p16 positive, which could have 
restricted the ability to draw meaningful conclusions 
about the outcomes in these patients. Nevertheless, these 
contradictory ﬁ ndings underscore the necessity to further 
assess the role of HPV in the setting of recurrent or 
metastatic disease (panel). Prospective assessment will be 
necessary to conﬁ rm tumour HPV status as a predictive 
biomarker for anti-EGFR therapy in recurrent or 
metastatic SCCHN.
We noted no unexpected safety ﬁ ndings. Frequency of 
skin toxicity, hypomagnesaemia, hypokalaemia, 
diarrhoea, and dehydration were generally consistent 
with that reported with other anti-EGFR monoclonal 
antibodies in patients with recurrent or metastatic 
SCCHN.9,46 These events have also been reported in 
patients receiving panitumumab with or without 
chemotherapy for metastatic colorectal cancer.47–49 The 
subjectivity of grading of skin toxicity, the use of diﬀ erent 
grading scales, and diﬀ erences in the descriptive terms 
for skin toxicity between our trial and EXTREME9 make 
comparisons of the frequency of skin toxicity between 
the two studies diﬃ  cult. 
Compliance with chemotherapy in both groups in our 
study was good. Exposure to cisplatin or carboplatin was 
similar across the groups, and exposure to ﬂ uorouracil 
was moderately greater in the group that received 
chemotherapy plus panitumumab (probably because of 
the reduced disease progression rate).
In conclusion, the addition of panitumumab to 
chemotherapy did not improve overall survival of 
patients with recurrent or metastatic SCCHN. However, 
signiﬁ cant improvements were noted with the addition 
of panitumumab in terms of PFS and the number of 
patients who achieved an objective response. Subgroup 
analyses suggested that clinical beneﬁ t may have been 
greater among certain patient subgroups, although 
these data should be interpreted with care given the 
small size of some of the groups. Furthermore, our 
retrospective analyses suggested that tumour p16 status 
might have both prognostic and predictive value in 
patients with recurrent or metastatic SCCHN treated 
with panitumumab combined with chemotherapy, 
although these ﬁ ndings require further validation.
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